Abstract
Previous versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM) did not allow the possibility of diagnosing attention-deficit/hyperactivity disorder (ADHD) in individuals with autism spectrum disorder (ASD). However, this veto has been removed in the current version of the DSM (DSM-5), highlighting the need for screening and appropriately managing, when present, symptoms of ADHD (i.e., inattention and/or hyperactivity/impulsivity) in individuals with ASD. Evidence from neuroimaging and genetic studies points to shared but also specific neurobiological underpinnings across the two disorders. While there is a large body of research on the pharmacological and non-pharmacological treatments of ADHD, evidence on the management of ADHD symptoms in individuals with ASD needs further investigation. Future studies should explore pathophysiologically based, rather than symptomatic, intervention strategies for ADHD associated with ASD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adler LD, Nierenberg AA (2010) Review of medication adherence in children and adults with ADHD. Postgrad Med 122:184–191
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn, DSM-5. American Psychiatric Publishing, Washington, DC
Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E et al (2007) Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61:545–550
Antshel KM, Zhang-James Y, Faraone SV (2013) The comorbidity of ADHD and autism spectrum disorder. Expert Rev Neurother 13:1117–1128
Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237–248
Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M (2011a) Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database Syst Rev (6):CD007813
Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X et al (2011a) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–169
Cheng JY, Chen RY, Ko JS, Ng EM (2007) Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 194:197–209
Cohen J (1992) A power primer. Psychol Bull 112:155–159
Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT (1980) Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 19:665–677
Conners CK, Sitarenios G, Parker JD, Epstein JN (1998a) Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26:279–291
Conners CK, Sitarenios G, Parker JD, Epstein JN (1998b) The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26:257–268
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M et al (2013) Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 54:227–246
Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW et al (2015a) Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 54:164–174
Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L et al (2015b) Safety of methylphenidate and atomoxetine in children with Attention-Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs 29(10):865–77
Cunill R, Castells X, Tobias A, Capella D (2013) Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf 22:961–969
Daley D, Van der Oord S, Ferrin M, Danckaerts M, Doepfner M, Cortese S et al (2014) Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry 53:835–847
Dinnissen M, Dietrich A, van den Hoofdakker BJ, Hoekstra PJ (2015) Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder. Expert Opin Drug Metab Toxicol 11:111–124
Dougherty CC, Evans DW, Myers SM, Moore GJ, Michael AM (2015) A comparison of structural brain imaging findings in autism spectrum disorder and Attention-Deficit Hyperactivity Disorder. Neuropsychol Rev 26(1):25–43
Elbe D, Lalani Z (2012) Review of the pharmacotherapy of irritability of autism. J Can Acad Child Adolesc Psychiatry 21:130–146
Faraone SV, Biederman J (2002) Efficacy of Adderall for attention-deficit/hyperactivity disorder: a meta-analysis. J Atten Disord 6:69–75
Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19:353–364
Faraone SV, Biederman J, Mick E (2006a) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36:159–165
Faraone SV, Biederman J, Spencer TJ, Aleardi M (2006b) Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 8:4
Feldman HM, Reiff MI (2014) Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 370:838–846
Ghanizadeh A (2013) Atomoxetine for treating ADHD symptoms in autism: a systematic review. J Atten Disord 17:635–640
Gray CA (1993) The original social stories book. Future Horizons, Arlington
Grzadzinski R, Di MA, Brady E, Mairena MA, O’Neale M, Petkova E et al (2011) Examining autistic traits in children with ADHD: does the autism spectrum extend to ADHD? J Autism Dev Disord 41:1178–1191
Hanwella R, Senanayake M, de Silva V (2011) Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 11:176
Horner RH, Carr EG, Strain PS, Todd AW, Reed HK (2002) Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 32:423–446
Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P et al (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988
Kirino E (2014) Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children. Clin Med Insights Pediatr 8:17–30
Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–744
Kovshoff H, Williams S, Vrijens M, Danckaerts M, Thompson M, Yardley L et al (2012) The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician’s point of view. Eur Child Adolesc Psychiatry 21:87–99
Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL (2008) Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2:25
Lecavalier L (2006) Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 36:1101–1114
Maia CR, Cortese S, Caye A, Deakin TK, Polanczyk GV, Polanczyk CA et al (2014) Long-Term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis. J Atten Disord, in press
Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH et al (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110–1119
Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J et al (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125–1127
McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M et al (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142–1148
Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS et al (2009) MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48(5):484–500
Nass RD (2005) Evaluation and assessment issues in the diagnosis of attention deficit hyperactivity disorder. Semin Pediatr Neurol 12:200–216
Nijmeijer JS, Arias-Vasquez A, Rommelse NN, Altink ME, Anney RJ, Asherson P et al (2010) Identifying loci for the overlap between attention-deficit/hyperactivity disorder and autism spectrum disorder using a genome-wide QTL linkage approach. J Am Acad Child Adolesc Psychiatry 49:675–685
Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533–1540
Pliszka S (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894–921
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948
Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43(2):434–42
Proal E, Gonzalez-Olvera J, Blancas AS, Chalita PJ, Castellanos FX (2013) Neurobiology of autism and attention deficit hyperactivity disorder by means of neuroimaging techniques: convergences and divergences. Rev Neurol 57(Suppl 1):S163–S175
Reichow B, Volkmar FR, Bloch MH (2013) Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord 43:2435–2441
Reiersen AM, Constantino JN, Grimmer M, Martin NG, Todd RD (2008) Evidence for shared genetic influences on self-reported ADHD and autistic symptoms in young adult Australian twins. Twin Res Hum Genet 11:579–585
Rhodes C (2014) Do Social Stories help to decrease disruptive behaviour in children with autistic spectrum disorders? A review of the published literature. J Intellect Disabil 18:35–50
Scahill L, Aman MG, McDougle CJ, Arnold LE, McCracken JT, Handen B et al (2009) Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J Autism Dev Disord 39:720–729
Schachter HM, Pham B, King J, Langford S, Moher D (2001) How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475–1488
Schwartz S, Correll CU (2014) Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 53:174–187
Sharma A, Shaw SR (2012) Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis. J Pediatr Health Care 26:291–299
Simon V, Czobor P, Balint S, Meszaros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204–211
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M et al (2013) Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 170:275–289
Tanaka Y, Rohde LA, Jin L, Feldman PD, Upadhyaya HP (2013) A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions. J Child Adolesc Psychopharmacol 23:262–270
Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J et al (2004) European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):I7–I30
Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM (2008) Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 28:783–800
WHO (1992) The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines 1992; diagnostic criteria for research 1993. Geneva 1992
Zaman R (2015) Transcranial magnetic stimulation (TMS) in Attention Deficit Hyperactivity Disorder (ADHD). Psychiatr Danub 27(Suppl 1):530–532
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix. Management of Disruptive Behaviors (Other Than ADHD) in Children and Adolescents with ASD
Appendix. Management of Disruptive Behaviors (Other Than ADHD) in Children and Adolescents with ASD
In a sizable portion of patients with ASD referred to child and adolescent mental health services, the main concerns include not only typical ADHD core symptoms (i.e., hyperactivity, inattention, and impulsivity) but also related disruptive behaviors such as physical aggressiveness, temper outbursts, or irritability, the latter being defined as an abnormal disposition to uncontrolled anger or aggression (Elbe and Lalani 2012). Although the prevalence of such maladaptive behaviors has not systematically been evaluated in children/adolescents with ASD, individual studies show that they are frequent and impairing in this population. For example, a study in a sample of 487 young people with pervasive developmental disorder (PDD) showed that up to 30 % of them presented with symptoms of irritability, including aggression (24.5 %), severe tantrums (30.2 %), and deliberate self-injurious behavior (16 %) (Lecavalier 2006).
Empirical evidence is available for both pharmacological and non-pharmacological strategies aimed to manage such impairing behaviors. Non-pharmacological interventions are grounded on behavioral techniques such as stimulus-based procedures (e.g., altering antecedent events), instruction-based procedures (e.g., instruction of appropriate behaviors), extinction-based procedures (e.g., withholding or minimizing presumed reinforcers), reinforcement-based procedures (e.g., increasing desired behaviors), punishment-based procedures (e.g., reducing behavior by delivering a contingent event), and systems change procedures (e.g., altering structural features of environment) (Horner et al. 2002). Although no formal meta-analyses have been published on the efficacy (and safety) of these behavioral interventions, a comprehensive research synthesis concluded that (1) disruption/tantrum was the most likely behavior targeted by such interventions, with aggression being the second most likely; (2) early use of behavioral interventions results in reductions of problem behaviors by 80–90 %; (3) interventions based on functional assessment are more likely to reduce the severity and frequency of disruptive behaviors (Horner et al. 2002).
Another promising and relatively novel intervention is based on Social Stories, originally developed to teach children with autistic spectrum disorders how to play games while increasing their ability to interact with others in a socially appropriate way (Gray 1993). Such stories are written to reflect a situation that the child with ASD finds difficult and provide information on what is happening, why, and which are the desirable responses in that specific social situation. A systematic review of case series reported so far concluded that across all seven research articles retrieved, 13 of 15 participants demonstrated a decrease in the frequency of disruptive behavior, with only two participants recording no change in behavior following the Social Story intervention (Rhodes 2014). It is worthy to point out that a rigorous meta-analysis of the efficacy/effectiveness of non-pharmacological interventions for disruptive behaviors in children with ASD, taking into account the level of blinding of raters, for example, a recent meta-analysis on non-pharmacological interventions for ADHD (Sonuga-Barke et al. 2013), is currently lacking in the field.
With regard to pharmacological treatments, although, as pointed out in the main chapter, no medication is currently approved to treat the core symptoms of ASD, there is an extensive practice, and an increasing evidence base, for the use of several agents to reduce the intensity and frequency of disruptive behaviors associated with ASD. Most of the evidence pertains to antipsychotics, in particular risperidone. The body of research on risperidone for disruptive behaviors has been recently meta-analytically reviewed pooling data from 16 open-label studies and 6 placebo-controlled trials (Sharma and Shaw 2012). This meta-analysis concluded that the sample weighted mean effect size for risperidone was 1.13 for open-label studies and 1.21 for placebo-controlled studies, thus indicating, in both cases, high efficacy of risperidone on ASD-related disruptive behavioral, according to the Cohen’s classification of effect size (Cohen 1992). In terms of tolerability and safety, the most common adverse events (AEs) reported in trials of risperidone for ASD included excessive weight gain [e.g., in the Research Units on Pediatric Psychopharmacology (RUPP) study (McDougle et al. 2005): 2.7 ± 2.9 kg vs. 0.8 ± 2.2 kg in the control group], increased appetite, fatigue, drowsiness, dizziness, and drooling. Follow-up data indicate that after 6 months of treatment, risperidone leads to a mean weight gain of about 5 kg, which exceeds developmentally expected norms (Martin et al. 2004). Prolactin levels tend to increase significantly: for instance, after 8 weeks, a fourfold increase has been observed, with a slight decrease after 6 months. Of note, prolactin levels were not associated with any adverse events (Anderson et al. 2007).
Another agent that has been increasingly investigated over the past years is aripiprazole. Two published placebo-controlled randomized trials (Owen et al. 2009; Marcus et al. 2009) assessing the effects of this drug for disruptive behaviors in children with ASD reported a statistically significant reduction of disruptive symptoms favoring aripiprazole (dose: 5–15 mg/day). In the first trial (Owen et al. 2009), discontinuation rates due to adverse events (AEs) were 10.6 % for aripiprazole and 5.9 % for placebo. Extrapyramidal symptom-related AE rates were 14.9 % for aripiprazole and 8.0 % for placebo. Mean weight gain was 2.0 kg with aripiprazole and 0.8 kg with placebo at week 8. No serious AEs were reported. In the second study (Marcus et al. 2009), sedation was the most common AE leading to discontinuation. Presyncope (at the dose of 5 mg/day) and aggression (at 10 mg/day) were the two severe AEs reported during the study. At week 8, mean weight change was +0.3 kg on placebo, +1.3 kg on aripiprazole 5 mg/day, +1.3 kg on aripiprazole 10 mg/day, and 1.5 kg on aripiprazole 15 mg/day.
This body of evidence has led the Food and Drug Administration to approve first risperidone (www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm) and, more recently, aripiprazole (www.online.lexi.com) for the treatment of irritability associated with autism spectrum disorder in children aged 6–17 years, and by contrast, in Europe, the European Medicines Agency has approved risperidone for the short-term treatment of aggressive or disruptive behaviors in children with subaverage intellectual level and disruptive behavior from the age of 5 years (www.medicines.org.uk/emc/medicine/12818/SPC/).
Other agents that have been assessed for the management of ASD-related disruptive behaviors include typical antipsychotic such as haloperidol [e.g., (Cohen et al. 1980)], although their possible side effects, including sedation, acute dystonia, and withdrawal dyskinesias, do not make this class as first-line option. Research on other drugs, such as antiepileptic (lamotrigine and levetiracetam), amantadine, and carnitine, has not shown so far clear beneficial effects of these agents on disruptive behaviors in children with ASD (Kirino 2014).
With regard to the sequencing of treatments (pharmacological and non-pharmacological), the National Institute for Health and Care Excellence (NICE) guidelines recommended using medication for behavioral problems in ASD only if environmental, psychosocial, or other interventions have been insufficient or cannot be delivered because of the severity of the behavior (https://www.nice.org.uk/guidance/qs51). Many experts in the field [e.g., (Dinnissen et al. 2015; Scahill et al. 2009)] concur with the view that pharmacological treatments should be considered only as short-term option when there is a history of behavioral symptoms that occur in multiple settings and that do not respond to behavioral interventions.
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Cortese, S. (2016). Attention-Deficit Hyperactivity Disorder and Autism Spectrum Disorder. In: Mazzone, L., Vitiello, B. (eds) Psychiatric Symptoms and Comorbidities in Autism Spectrum Disorder. Springer, Cham. https://doi.org/10.1007/978-3-319-29695-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-29695-1_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29693-7
Online ISBN: 978-3-319-29695-1
eBook Packages: MedicineMedicine (R0)